Published in Lab Law Weekly, August 19th, 2005
The company also announced new business initiatives that will leverage Nanobac's growing intellectual property estate to take advantage of diagnostic and therapeutic opportunities.
Since 1988 researchers at Nanobac Life Sciences, Inc., have been studying a pathogen that they believe is responsible for numerous chronic diseases affecting humankind. They called this pathogen nanobacteria because of its small size, roughly 100 billionths of a meter, and because of its ability to replicate or propagate.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.